Nurizzati Sudarmaji, - and Nurolaini Kifli, - and Andi Hermansyah, - and Siang Fei Yeoh, - and Bey-Hing Goh, - and Long Chiau Ming, - (2022) Prevention and Treatment of Monkeypox: A Systematic Review of Preclinical Studies. Viruses, 14 (11). pp. 1-39. ISSN 1999-4915

	Text (FULLTEXT) Bukti Artikel C-8.pdf Download (4MB)
	Text (Kualitas Karil) Bukti Validasi dan Penilaian Karil C-8.pdf Download (387kB)
	Text (Similarity) Bukti Similarity C-8.pdf Download (7MB)
	Text (Korespondensi) Bukti Korespondensi C-8.pdf Download (1MB)

Abstract

The outbreak of monkeypox, coupled with the onslaught of the COVID-19 pandemic is a critical communicable disease. This study aimed to systematically identify and review research done on preclinical studies focusing on the potential monkeypox treatment and immunization. The presented juxtaposition of efficacy of potential treatments and vaccination that had been tested in preclinical trials could serve as a useful primer of monkeypox virus. The literature identified using key terms such as monkeypox virus or management or vaccine stringed using Boolean operators was systematically reviewed. Pubmed, SCOPUS, Cochrane, and preprint databases were used, and screening was performed in accordance with PRISMA guidelines. A total of 467 results from registered databases and 116 from grey literature databases were screened. Of these results, 72 studies from registered databases and three grey literature studies underwent full-text screening for eligibility. In this systematic review, a total of 27 articles were eligible according to the inclusion criteria and were used. Tecovirimat, known as TPOXX or ST-246, is an antiviral drug indicated for smallpox infection whereas brincidofovir inhibits the viral DNA polymerase after incorporation into viral DNA. The ability of tecovirimat in providing protection to poxvirus-challenged animals from death had been demonstrated in a number of animal studies. Non-inferior with regard to immunogenicity was reported for the live smallpox/monkeypox vaccine compared with a single dose of a licensed live smallpox vaccine. The trial involving the live vaccine showed a geometric mean titre of vaccinia-neutralizing antibodies post two weeks of the second dose of the live smallpox/monkeypox vaccine. Of note, up to the third generation of smallpox vaccines—particularly JYNNEOS and Lc16m8—have been developed as preventive measures for MPXV infection and these vaccines had been demonstrated to have improved safety compared to the earlier generations.

Actions (login required)

View Item